search
Back to results

Lymph Node Dissection Before Or After Cystectomy (LBOACP)

Primary Purpose

Bladder Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
Lymph node dissection before bladder resection
Lymph node dissection after bladder resection
Sponsored by
Jagiellonian University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bladder Cancer focused on measuring Bladder Cancer, Muscle-invasive bladder cancer, Radical cystectomy, Lymph node dissection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients undergoing radical cystectomy for bladder cancer in the Department of Urology University Hospital in Krakow Exclusion Criteria: Previous pelvic lymph node dissection

Sites / Locations

  • Department of Urology, University Hospital, Jagiellonian UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

1 Lymph node dissection before bladder resection

2 Lymph node dissection after bladder resection

Arm Description

Lymph node dissection will be performed before bladder resection during radical cystectomy

Lymph node dissection will be performed after bladder resection during radical cystectomy

Outcomes

Primary Outcome Measures

Early complications rate
Complications rate within 30 postoperative days

Secondary Outcome Measures

Lymph node yield
Number of lymph nodes removed
Operative time
Total operative time, bladder resection time, lymph node dissection time

Full Information

First Posted
June 6, 2023
Last Updated
July 28, 2023
Sponsor
Jagiellonian University
search

1. Study Identification

Unique Protocol Identification Number
NCT05939856
Brief Title
Lymph Node Dissection Before Or After Cystectomy
Acronym
LBOACP
Official Title
Lymph Node Dissection Before Or After Cystectomy - Pilot Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 28, 2023 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jagiellonian University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare different ways of performing surgery for bladder cancer. Specifically, the goal is to determine whether it is better to remove the lymph nodes before removing the bladder or after removing the bladder during radical cystectomy. The study aims to answer two main questions: Does the order of surgical steps during radical cystectomy affect the occurrence of complications after surgery? Does the order of surgical steps during radical cystectomy impact the duration of the operation and the number of lymph nodes removed? Participants in the study will be randomly assigned to one of two groups. One group will undergo lymph node removal before bladder resection, while the other group will have lymph node removal after bladder resection during radical cystectomy. Throughout their hospital stay and for 30 days following the operation, participants will be closely monitored for various factors including operative details, pathology results, and any complications that may arise.
Detailed Description
Lymph node dissection (LND) is an integral part of radical cystectomy (RC) for bladder cancer. LND provides important diagnostic and prognostic information, and according to most studies, is associated with therapeutic benefit. The optimal extent and template for LND in bladder cancer remains to be established. Currently, there are no specific recommendations regarding the sequence of lymph nodes removal and bladder resection during radical cystectomy, and the decision is based mainly on individual surgeon preference. The aim of the LBOAC pilot randomized trial is to evaluate the difference in intraoperative parameters and postoperative outcomes between patients undergoing LND before bladder resection during RC and those undergoing LND after bladder resection during RC. LBOAC is a pilot randomized controlled trial with two parallel groups. The primary objective of the trial is the comparison of complication rate within 30 postoperative days. Secondary objectives of LBOAC include comparing lymph node yield and operative time between the two groups. Data for will be collected using electronic case report forms (eCRFs) at baseline and within 30 days after the surgery. This pilot study is designed to test feasibility of, to support the refinements of the protocol and to aid in sample calculation that can be used for larger scale trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bladder Cancer
Keywords
Bladder Cancer, Muscle-invasive bladder cancer, Radical cystectomy, Lymph node dissection

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1 Lymph node dissection before bladder resection
Arm Type
Other
Arm Description
Lymph node dissection will be performed before bladder resection during radical cystectomy
Arm Title
2 Lymph node dissection after bladder resection
Arm Type
Other
Arm Description
Lymph node dissection will be performed after bladder resection during radical cystectomy
Intervention Type
Other
Intervention Name(s)
Lymph node dissection before bladder resection
Intervention Description
Lymph node dissection before bladder resection
Intervention Type
Other
Intervention Name(s)
Lymph node dissection after bladder resection
Intervention Description
Lymph node dissection after bladder resection
Primary Outcome Measure Information:
Title
Early complications rate
Description
Complications rate within 30 postoperative days
Time Frame
Within 30 days after the surgery
Secondary Outcome Measure Information:
Title
Lymph node yield
Description
Number of lymph nodes removed
Time Frame
When pathology report is available (on average, the pathology report is available within 14 days after the surgery)
Title
Operative time
Description
Total operative time, bladder resection time, lymph node dissection time
Time Frame
At the end of the surgery (after the completion of skin closure and wound dressing)
Other Pre-specified Outcome Measures:
Title
Intraoperative complications rate
Description
Intraoperative complications rate
Time Frame
At the end of the surgery (after the completion of skin closure and wound dressing)
Title
Positive surgical margin rate
Description
Positive surgical margin rate
Time Frame
When pathology report is available (on average, the pathology report is available within 14 days after the surgery)
Title
Ureters clamping time
Description
Ureters clamping time
Time Frame
At the end of the surgery (after the completion of skin closure and wound dressing)
Title
Postoperative estimated glomerular filtration rate (eGFR)
Description
eGFR on postoperative day 1 and day 4-7
Time Frame
Within 7 days after the surgery
Title
Complications severity and type
Description
Severity and type of complications
Time Frame
Within 30 days after the surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing radical cystectomy for bladder cancer in the Department of Urology University Hospital in Krakow Exclusion Criteria: Previous pelvic lymph node dissection
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anna K. Czech, M.D.
Phone
+48124002500
Email
aka.czech@uj.edu.pl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anna K. Czech
Organizational Affiliation
Jagiellonian University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Urology, University Hospital, Jagiellonian University
City
Krakow
ZIP/Postal Code
30-688
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna K Czech, M.D.
Phone
0048124002500
Email
aka.czech@uj.edu.pl
First Name & Middle Initial & Last Name & Degree
Katarzyna Gronostaj, Ph.D.
Phone
0048124002500
Email
katarzyna.gronostaj@uj.edu.pl

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Lymph Node Dissection Before Or After Cystectomy

We'll reach out to this number within 24 hrs